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Metabolomics aims to study the biological processes that take place in human body
and  their  outcome  molecules,  the  metabolites.  Nowadays,  the  importance  of
metabolomics is in an upward trend because it has a huge number of clinical and
analytical  applications.  Along this  work,  several  topics  will  be  treated.  From the
different biological matrices where metabolomics can be applied to some of the main
known disease  biomarkers.  To  finish  specific  characteristics  of  diseases  such  as
ovarian or breast cancer will be discussed.
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The main reason to choose this project is its modernity as well as my personal interest
about this hot topic. In the last years, many studies have been performed showing that
metabolomics is a very useful tool in the diagnostic of several diseases. Furthermore,
applications  in  prognostic  have  also  been  found.  These  scientific  advances  are
important  for  all  of  us because  they could be the main  tool  for  discovering new
diagnostic and prognostic disease biomarkers in the next years.
1.2- Objective
The main objective of this work is to research and write a review about metabolomics
and  their  applications.  Besides,  it  also  deeps  intoens  some  aspects  such  as  the
different biological matrices analysed or specific disease biomarkers discovered.
1.3- Methodology
To carry out this work I have searched in different academic sources such as books
and journals in order to be able to explain what metabolomics are, as well as their
characteristics and most relevant aspects.
Despite having some general ideas about metabolomics,  I have had to deepen my
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knowledge in this interesting topic. I have also used websites and academic articles
that have been of great help in understanding the whole metabolomics workflow.
1.4- Acknowledgements
First of all, I would like to appreciate the help and the advices that my supervisor
Juan Vicente Sancho Llopis has given to me. I also want to mention all my degree
teachers  and  express  thanks  to  them  for  everything  that  i  have  learned  about
chemistry.
2- Introduction to metabolomics
2.1- Definition
Metabolomics are a branch of the called “omics cascade” which aims to study and
research about metabolites in biological samples and how that could help to know
more or to prevent diseases. Those metabolites are many different small molecules
that take part in general metabolic reactions and in the normal function of every cell.
The “omics cascade” comprehend genomics, transcriptomics, proteomics ,
and metabolomics, from more to less complex analytes. These sciences will guide
ourselves to a better comprehension of the biochemical and biological mechanisms
that happen in living organisms. Although the metabolome involves a big complexity
in  its  study  as  a  wide  variety  of  biomolecules  and  biochemical  mechanisms  are
7
implicated, it is a fact that in the last years the number of metabolomics publications
has increased dramatically. Therefore, metabolomics has reached its maturity and it 
is achieving more importance every day.
Nowadays,  there  are  two  main  approaches:  metabolic  profiling  and  metabolic
fingerprinting.
2.2- Metabolic profiling and metabolic fingerprinting
The  metabolic profiling approach studies directly a target group of metabolites that
typically take part in the same metabolic pathway such as the metabolites present in
the Krebs cycle, or those which come from fatty acids. The metabolic profiling [1] is
a  quantitative  analysis  that  comprehend  targeted  analysis  of  a  few  number  of
analytes. This approach is often used in a driven-hypothesis rather than generating
another one. Lately an effort has been made to build databases of these metabolites
with the objective of improving the understanding about biological pathways, but it is
a quest not completed yet.
In the other hand, we have the metabolic fingerprinting which is more a qualitative
analysis (it allows to study simultaneously a wide range of metabolites). The aim of
this  approach is  to  identify  patterns  of  analytes  in  the way to observe  variations
caused by an intoxication, a disease, or a change in the diet. A good example for the
application  of  this  approach  could  be  the  monitoring  of  a  disease  in  humans.
Observing the two metabolic patterns (one for healthy patients and another for ill
patients) we could know, for example, if an specific treatment has been successful or
not and prevent unexpected relapses.
It is remarkable, not only the metabolic fingerprinting of intracellular metabolites, but
the metabolites that are excreted by the cells to the intercellular medium which could
give big amounts of information about phenotypical changes. This approach is called
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metabolic footprinting.
Combining  both  tools  (profiling  and  fingerprinting)  it  is  possible  to  find  new
biomarkers. Acquire biological knowledge and, at the same time, diagnose diseases
and  evaluate  the  pharmacological  efficiency  could  be  the  results  of  a  correct
integration of both approaches .
2.3- Metabolomics workflow
From NMR to direct MS or injection into chromatography coupled to MS, a variety
of  instruments  have  been used  for  metabolomics  applications.  Mass  spectrometry
analytical  platform has  been  proved  to  be  the  one  which  produce  better  results.
Mostly  comparing  with  NMR,  MS  analysis  is  able  to  study  a  wider  range  of
biomarkers in the way of its higher selectivity and sensitivity. However, a sample
preparation  previous  step  is  needed  for  MS-coupled  analysis  [1].  Typically,  the
acquisition  in  both  LC-MS and GC-MS is  performed  with  the  aim to  widen the
chemical domain of the measured metabolites.
Actually, the obtained data is as valid as the sample preparation and experimental
workflow and design.
Sampling is a key step in metabolomics workflow due to the influence of biological
variability and the need of the obtaining of statistically validated data. In particular,
when studying human samples, the influences of diet, gender, age and genetic factors
have to be considered. In order to assure the representativity of the samples, quality
controls samples such as samples replicates or blank samples must be analyzed. Also
minimizing  the  formation  or  degradation  of  metabolites  after  sampling  due  to
remaining enzymatic activity or oxidation processes are required.
Sample preparation is the next step in metabolomics workflow, mainly it will extract
the analytes from complex biological matrices (plasma, serum, urine, saliva among
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others) with the purpose of convert them into a compatible form with the analytical
equipment. In the case of low-abundance metabolites, the extraction procedure can
include  a  pre-concentration  step  to  achieve  the  detection  limits  of  the  applied
analytical technique [1]. Sample extraction should be as easy as possible in order to
minimize the losses of analytes. It is important to say that in every sample extraction
process  analytes  are  lost,  especially  in  extraction  procedures  applied  to  aqueous
samples.Several methods could be used for this process and it only depends on the
sample matrix. The main sample preparation processes are  liquid-liquid extraction
(LLE), solid-phase extraction (SPE), supercritical fluid extraction, accelerated solvent
extraction,  microwave-assisted  extraction,  protein  precipitation,  and  membrane
methods, such as dialysis or ultracentrifugation [1].
Once sample preparation is done, it is time to the data acquisition and its analysis.
Both NMR and MS techniques follow two steps for data acquisition and processing.
These steps are: 1) Processing of raw data with the purpose of peak identification,
peak picking and normalization in order to have a comparison between samples. 2)
Data analysis with the purpose of extract the analytical information and to elucidate
biomarkers.
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Figure 1: General metabolomic workflow
2.3.1- Instrumental equipment
MS-based techniques usually are the best option to carry out metabolomics and they
have very different features [2].
1) High Performance Liquid Chromatography (HPLC) is the most used technique in
the biological field. It is compatible with several stationary phases but reverse phase
is the most used and it is able to retain hydrophobic molecules. However, samples in
metabolomics could be biofluids which have many polar metabolites so reverse phase
is  not  suitable  on  these  circumstances.  An  option  for  the  retaining  of  polar
metabolites is hydrophilic interaction chromatography (HILIC), a new approach that
is becoming popular because allows a complementary separation to the reverse phase.
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Furthermore,  in  the  last  years  the  ultra-high-pressure  liquid  chromatography
(UHPLC)  has  emerged.  This  separation  method  employs  columns  packed  with
particles of very small diameter (1.7μm) achieving a greater resolution for separation
but increasing dramatically the pressure.
2) Electrospray ionization (ESI) is an interface which provides a gentle and sensitive
ionization of the compounds. It is capable of ionize the molecules due to protonation
and/or deprotonation processes
3)  Quadrupole  Time-of-Flight  Mass  Spectrometer  (QTOF-MS) is  a  type  of  high
resolution mass spectrometry (HRMS). Ions are blocked from the source and they are
accelerated down to the detector. The ions which have a lower m/z would arrive first
to the detector while higher m/z ions would arrive later. The time that an ion flies is
correlated with its m/z with high mass accuracy. QTOF-MS systems consist
of a quadrupole, a collision cell and a TOF analyzer, which allows to confirm known
metabolites or elucidate some structures of unknown metabolites.
4) Ion Mobility Spectrometry (IMS) is a powerful technique that is usually coupled to
a  MS  technique  to  achieve  better  results.  The  most  remarkable  coupling  in
metabolomics is the once with UHPLC quadrupole time-of-flight mass spectrometer
(UHPLC-IMS-QTOF MS) system because it  allows to  maximize  the detection of
metabolites without increasing the analysis time. IMS is a gas-phase ion separation
technique under atmospheric pressure based on their mobility which correlated with
the 3D shape of the ion, adding an extra identification parameter, mainly for isomers
discrimination.
However,  NMR  and  MS  techniques  have  advantages  and  disadvantages  in
metabolomic  studies.  While  mass  spectrometry  has  the  advantage  of  being  more
sensitive than NMR (at the level of picograms), this sensitivity is not independent,
because it is huge influenced by the pK of metabolite and its hydrophobicity. This
feature might  be a problem because while polar  metabolites  would be able to be
detected with the action of  the  electrospray,  the non polar  metabolites  may need
atmospheric pressure chemical  ionization.  Moreover, some independent conditions
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could affect dramatically the obtained results. These conditions use to be quenching,
sample conservation and extraction.
In NMR analysis is preferable to avoid a complex sample preparation, especially in
biofluids with low molecular weight biomarkers such as urine. Other biofluids which
are plasma and serum need an extraction or a weight technique to divide the polar
from the non polar metabolites. For MS analysis an exhaustive extraction is needed
and  many  times  the  tissue  is  destroyed  with  the  objective  of  eliminate  all  the
interferences  and  picking  up  the  wanted  metabolites.  Although  it  need  a  more
invasive methodology, MS analysis usually reflects better sensitivity in metabolites
detection.
2.3.2- Data processing
There are several data processing softwares which are able to process big amounts of
raw data and they are used in many differents fields. They usually show 3D graphs,
including retention time, m/z and intensity, but in metabolomics 4D graphs could be
used with Progenesis  QI  software.  The Progenesis  QI  program allows  to  include
collision cross section in the shown data. The inner workflow for data processing in
this software is: 1) Import data 2) Select of possible adducts present in your sample 3)
Show graph of retention time vs m/z 4) Run alignment 5) Peak picking
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2.3.3- Data analysis
Data analysis is the next and final step in metabolomic workflow. Although several
software could be used for this step, they usually share principal component analysis
(PCA)  as  main  tool.  PCA is  a  non-supervised  analysis  method  with  the  aim of
achieve a clear differentiation between samples with the least number of principal
components  and  with  the  greatest  degree  of  confidence.  This  method  works
identifying patterns,  similarities  and differences  without  any previous  information
about the samples content.
After PCA, a supervised analysis should be done with the purpose of improve the
understanding of which variables are the responsible of the differentiation between
groups.  For  supervised  analysis  previous  information  of  sample  is  given.  These
supervised techniques are known as discriminant analysis and among them we can
find the Partial Least Squares-Discriminant Analysis (PLS-DA) and orthogonal-PLS-
DA (OPLS-DA).  In  PLS-DA method,  the  previous  given  information  is  used  to
distinguish between groups which have been already predetermined.
OPLS-DA method is used to create high predictive models in order to reprocess the
data and facilitating the identification of potential biomarkers.
For  biomarkers  elucidation  there  usually  are  metabolite  libraries  available,  which
contain mass spectra of metabolites found in specific biological samples and found by
a specific equipment such as GC-MS or LC-MS. In elucidation of new metabolites,
additional  analytical  platforms  will  be  needed.  In  the  case  of  low-abundance
metabolites,   an  alternative  structure  elucidation  tool  usually  lacks  the  needed
sensitivity. However, for high-abundance metabolites, proton or other types of NMR
is the technique of choice for structure elucidation. 
Figure 2: Data processing and analysis process
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2.4- Biological matrices
Though metabolomics could be useful in almost every biological tissue or matrix,
there are some typical  biofluids,  such as urine,  serum, plasma and saliva or even
breath.
2.4.1- Urine
Urine is a transparent yellow-coloured fluid produced by mammals kidneys. Kidneys
filter bloodstream to take all kind of residues and excess water. The resulting urine
has large concentrations  of  urea,  salts,  organic  acids,  ammonia  and water-soluble
toxins. Among all biological fluids, [3] urine is such an interesting one. It is because
of its wide range of metabolites and  due to the availability of large quantities of this
fluid.  As a  biological  waste  fluid,  it  contains  breakdown metabolites  from foods,
drinks,  drugs,  environmental  pollutants  and  bacterial  by-products.  Besides,  it  is
usually  free from interfering proteins and lipids.  However, there could be several
variations between two different urine samples. It depends on more than 14 factors
where  diet,  individual  health  and  hydratation  have  been  proved  to  be  the  most
relevant.
For example, the urinary excretion of trans-ferulic acid (a polyphenolic derivative)
increases after the ingestion of breakfast cereals and chocolate.
Although urine concentration variability makes data normalization a must, [4] at least
a  half  of  the  published  articles  between  2012  and  2014  did  not  include  any
information about normalization.
Strategies  were  developed  with  the  aim  of  estimate  the  urine  concentration:  (i)
relative concentration to creatinine,. (ii) measurement of the total solute concentration
and. (iii) urine/pure water density ratio. These strategies work better when they are
combined.
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In  addition to  the urine concentration  variability,  analytical  drift  for  MS coupled
methods has also been observed. To compensate this effect, QCs (quality controls)
are used to assure the data stability during the experiment. These QCs are prepared
mixing  all  the  samples  analysed  in  the  same  batch,  therefore  its  composition
represents the average of all the samples.
Nowadays, more than 3000 different metabolites have been identified in human urine
and the number is still increasing.
Gagnebin  et al.  [4] reported the more abundant metabolites in urine. Theise values
were normalized as relative concentration to creatinine (10.4 ± 2.0 mM). They are
urea  (22.5  ±  4.4  mM/mM  creatinine),  hippuric  acid  (298.5  ±  276.8  mM/mM
creatinine) and citric acid (280.6 ± 115.2 mM/mM creatinine).
Observing some of the less concentrated metabolites (around 1 pM/mM creatinine)
we found that current lower limit of detection in UHPLC-MS for metabolites in urine
is  in  the  low  pM/mM  creatinine  range.  This  paper  also  assure  that  NMR  may
currently be the most comprehensive and certainly the most quantitative approach to
characterizing this biofluid. However, NMR technique has also drawbacks such as
the low sensitivity.
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Table 1: Classification of determined metabolites in urine
2.4.2- Plasma
Plasma is the non-cellular part of blood. It is the result of removing all cells and only
the non-living parts of blood remain. Its composition varies between different living
species biut also between people. In general, it is formed mainly by water (around
90%) and biomolecules such as proteins, lipids, vitamins or glucose among others.
A study [5] was developed to determine the number and relative concentration of
different  plasma  metabolites.  LC/GC-MS  technologies  were  used  for  that
determination in 269 healthy subjects with different ancestries. From Caucasian to
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Hispanic  and  Afro-American  males  and  females  aged  20-65.
Ethylenediaminetetraacetic  acid  (EDTA)  plasma  samples  were  collected  in  New
York. The results dropped that over 300 metabolites were identified and confirmed
by  using  LC  (60%)  and  GC  (40%).  Furthermore,  they  show  that  at  least  100
compounds suffer a huge variability with age, sex or race.
Concentration increase in citric cycle intermediates (isocitrate, D-ketoglutarate and
malate) for aged subjects. Significant differences in several cofactors and vitamins
were  observed as D-tocopherol, pantothenate and nicotinamide were higher in older
subjects too.
Metabolites changes between sex were found to be very few. Around 30 metabolites
present  significant  concentration  difference  between  men  and  women.
Ortophosphate, creatine and biomolecules associated with lipid metabolism such as
nonanedioate, myristate, palmitoleate, glycerol and E-hydroxybutyrate were in higher
levels  in  women.  Generally,  amino  acid  metabolism,  energy  metabolism  and
nucleotide metabolism were elevated in males relative to females.
Another  important  variable  to  study  was  the  body  mass  index  (BMI).  A  bigger
change in some of those “variable” biomarkers was found into subjects with higher
BMI than depending on sex, race or age.
Nowadays techniques have been developed increasing the qualitative detection range.
By observing changes in the activation of specific enzymes, analytical instruments
are able to find and identify more than 3000 plasma metabolites.  In 2012 [6],  an
experiment based on the inactivation of xanthine oxidoreductase (XOR) (an enzyme
that catalyzes the final steps in purine degradation) was carried out. The experiment
was  performed  with  LC-MS  coupled  with  a  multivariate  statistical  data  analysis
platform. In order to assure de reproducibility of the experiment 56 analyses were
performed. The results confirm that XOR is not only the terminal enzyme in purine
metabolism, catalyzing the oxidation of purine metabolites to uric acid, but it has also
been implicated as a determinant of adipogenesis and other key metabolic processes.
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2.4.3- Serum
Plasma is obtained from a blood sample, if anti-coagulants are introduced, by simply
processes such as centrifuging the sample and removing or decanting the non-cellular
portion. If no anticoagulant is added and the blood is allowed to clot, the supernatant
fluid is called the serum [7]. Both, plasma and serum are mainly formed by water
(around 95 %), but serum is less viscous because of his lack of coagulant proteins
such as fibrinogen and prothrombin. Although they look very similar, the presence of
cloting proteins changes hugely the identification of biomarkers. Psychogios et al. [7]
suggests that most abundant metabolites in serum are D-glucose (5 mM), cholesterol
(5 mM), melanin (5 mM), urea (4 mM), ATP (3 mM) and glyceraldehyde (1.5 mM).
However, the values were into a huge range of variation probably caused by age, sex
or others environmental factors. So, it is difficult to correlate one of those metabolites
with a specific disease
Experimentally,  a  combination  of  different  kind  of  methodologies  was  used  to
determine and identify the serum metabolites. Someo of those analytical platforms
were  high-resolution  NMR  spectroscopy,  GC-MS,  TLC/GC-MS,  LC/MS,  UPLC-
MS/MS, and direct flow injection (DFI) MS/MS.
Psychogios et al [7] reviewed some of the analytical platforms results.
Regarding  NMR  experiments,  they  are  simple  and  relatively  easy  to  perform.
Typically, around a 95 % of found metabolites could be identified.
For example, 53 serum samples were taken in an experiment by Psychogios et al [7].
The results  showed that  therey were  identified an average of  30 biomarkers  per
sample.
For the GC-MS experiments, many of the peaks that appear into chromatograms were
easily identified as well. However, around a 40 % of the peaks remain not identified.
This relatively low level of coverage is a common problem in global or untargeted
GC-MS caused  by the  lack  of  GC/MS metabolomics  library.  This  lack  is  still  a
problem for other popular methodologies such as all kind LC-MS analysis.
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Table 2: Chemical classes in the Serum Metabolome
2.4.4- Saliva
Saliva is a biofluid which is mainly composed by water (99%) as well as. Several
minor components including mucus,  digestive enzymes,  growth factors,  cytokines,
immunoglobulins, antibacterial peptides, bacterial cells and salts (Soini et al. 2010)
[8] . However, its chemical composition varies dramatically in response of situational
or environmental factors. Although saliva is very easy to obtain and it is abundant (on
average, a person generates between 0.75 and 1.5 L of saliva per day), rarely is used
for medical testing. The main reason is because it is not a not well known biofluid
and there is a lack of chemical information about it.  Dame et al. [9] were able to
identify around 800 saliva metabolites by using a multi analytical platform approach
and literature mining.
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Some  experiments  were  carried  out  to  find  these  metabolites  [9].  Samples  were
obtained from 16 subjects (8 males and 8 females) between 22 and 42 years. The
subjects  must  not  eat,  drink,  smoke  or  use  oral  hygiene  products  1  h before  the
sampling.  Samples were collected following Sugimoto  et  al.  [10] protocol.  Saliva
was collected by spitting into a 50 mL Falcon tube for 3 min. The average volume
collected was 2.5 mL.
For  NMR  spectroscopy,  deproteinization  is  needed  because  substances  such  as
mucous, proteins and other particulates can affect the sanalysis quality. The results
showed that the most abundant compounds in human saliva are acetic acid (6.8 mM),
propionic acid (1.4 mM), urea (0.61 mM) and L-lactic acid (0.53 mM).
For GC/MS, organic acids, polar and non-polar compounds were analyzed separately.
To  analyze  organic  acids,  the  ketoacids  have  to  be  converted  to  methoxime
derivatives and then extracted twice with ethyl acetate and diethyl ether, followed by
derivatization  with  N,O-bis(trimethylsilyl)trifluoroacetamide  (BSTFA)  [3].  To
analyze  the  non-polar  metabolites,  saponification  with  2  M sodium hydroxide  is
needed, followed by heating. Most abundant compounds were the same than NMR
analysis. However, number of identified metabolites by GC/MS were higher than in
NMR, based on its much higher sensitivity.
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Figure 3: overlap of salivary metabolites detected by NMR, GC–MS, DFI-MS/MS, ICP-MS, and
HPLC-coupled to MS, UV and fluorescence detection
2.4.5- Breath
Exhaled breath contains thousands of volatile organic compounds (VOCs) of which
the  composition  varies  depending  health  status,  age,  diet,  and  some  other
environmental  factors.  Those compounds have their  origin into the blood when it
reaches the lungs. Human brain is able to recognize more than 10000 different smells.
Besides, it is able to recognize good and bad smells without knowing the chemical
signals that is being registered.
Nowadays, modern technologies enable to identify some biomarkers present into the
human breath.
Boots et al reported that one of the generally accepted exhaled biomarkers [11] is
nitric oxide (NO), of which increased levels are associated with the occurrence of
pulmonary  inflammation  and  oxidative  stress  in  various  chronic  lung  diseases
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including asthma and chronic pulmonary diseases (COPD).
Another researchable and waiting for further study biomarker is carbon monoxide
(CO). Some studies, including Yamaya et al, found a correlation between CO exhaled
levels and certain and important lung functions [12]. However, it is very difficult to
assure  because  the  measured  CO  concentrations  are  usually  influenced  by
atmospheric CO.
Additionally, elevated levels of exhaled ethane and pentane are reported in patients
suffering  from several  chronic  lung diseases  including COPD,  asthma and cystic
fibrosis.
Usually, the determination of only one biomarker has no phenotypical results, so the
best way to understand the relevance of VOCs in human breath is to study all ofd
those compounds. The total number of exhaled VOCs is also called as volatome. By
studying  the  volatome  we  are  able  to  comprehend  processes  underlying  the
pathophysiologies of interest.
In  order  to  distinguish  biomarkers  of  disease  and  environmental  contaminant
compounds, reliable analytical methodologies have been developed. Sampling is a
sensitive stage, because it is easy to get interference compounds with the sample.
GC/MS  is  the  preferred  analytical  technique  because  it  is  a  commonly  applied
methodology to accurately measure trace gases in complex matrices. In addition, the
GC-MS technique is proven to be highly sensitive and robust. Besides, it has huge
degree of reproducibility.
Furthermore,  use  of  GC-TOF/MS  enables  to  deliver  more  spectral  information
because of the several advantages of using a TOF analyzer. Advantages of using TOF
for broad spectrum analysis includes increased mass accuracy and mass resolution,
greater  sensitivity,  rapid acquisition,  and increased dynamic  range when profiling
over a broad molecular weight range.  
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Figure 4: Usefulness of VOCs as biomarkers on the basis of important biomarker characteristics.
2.5 – Present and future perspectives
Although some metabolomics applications have been already commented, a review
of current and actual applications and future perspectives is needed.
Despite its utility in the clinical field, nowadays metabolomics is not still a must use
technique  in  the  health  world.  Metabolomics  rarely  outperform  the  traditional
methods so it is difficult to integrate the needed technologies in the standard health
services.  However,  their  utility  in  the  way  of  obtain  a  clearer  sight  of  diseases
(prognostic and diagnostic) and how they work [13], makes probable their integration
in a close future. Furthermore, some associations in several countries are developing
biobanks collecting metabolomic and other omics data with the purpose of carry out
multiple  layer  analysis  and assays.  Those experiments  would help to  know more
about biological processes and would give a clearer sight of several human diseases.
Recently, a set of metabolomic methods have been used for the creation of a disease
risk model. This model rate the risk of suffer from a certain disease with a score. Its
function  is  similar  than  the  traditional  model  but  with  an  outstanding  accuracy.
Currently,  this  model  has  been  proved  successfully  for  diseases,  like  pulmonary
diseases, and in traits like educational attainment. In this methodology, simple assays
are needed with the objective of follow up the disease development. For example, if a
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patient has risk to develop blood cancer, periodical simple assays of carcinogenic
cells would be carried out  to follow up the disease.  In addition,  metabolomics  is
expected to increase its power and sensitivity and not only be used for diagnostic and
prediction,  but  be  a  useful  tool  in  disease  treatment.  For  example,  metabolomics
could help the doctors to know if the patient is reacting well to an specific treatment
or drug, or if a disease has probabilities to be reproduced again in the patient.
3 - Disease biomarkers
Advances  in  metabolomics  allows  to  reach  novel  biological  insights  about
metabolites and correlated phenotype. Following this way of knowledge, we are able
to know more about disease biomarkers. Those biomarkers are very useful in clinical
medicine for prognostic or predictive purposes. In the next sections, some biomarkers
for stress oxidative diseases and for cancer disease are going to be commented.
3.1 - Oxidative stress related diseases
The oxidative or  nitrosative stress  is  produced by the failure  of  the antioxidative
cellular defenses to completely inactivate the reactive oxygen species (ROS) and the
reactive nitrogen species (RNS). The failure could be caused by massive production
of ROS/RNS, by a defect in the antioxidative defense system or both. This oxidative
stress affects to a huge quantity of different biomolecules which are proteins, nucleic
acid bases and lipids causing irreversible damages. These damages usually derive to
affect  cell  health and also to the production of  secondary reactives that  drives to
necrosis and apoptosis. Indeed, recent evidences have revealed that most of acute and
chronical human diseases have stress oxidative origin.
Some studies [14] have shown that stress oxidative processes have a big influence
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into aging process and aging diseases such as atherosclerosis,  ophthalmologic and
neurodegenerative diseases. Furthermore, it is known that aging is mainly caused by
an accumulation  of  oxidized species  in  tissues.  It  seems  to  be  a  disparity  in  the
concentration  of  those  oxidized  species  between  intracellular  and  extracellular
medium. The extracellular medium shows a bigger level of those species because of
the  turnover  between  intracellular  medium  and  because  of  the  difference  in
homeostatic control. Biomarkers are defined as characteristics that can be measured
and are representative of a biological process. ROS/RNS are not biomarkers because
of their low stability and half-time life so the ones used as  markers are the products
of  reaction  between  oxidative  and  nitrosative  molecules  and  biomolecules.  Some
general  biomarkers  allow  us  to  identify  several  diseases  which  have  an
oxidative/nitrosative origin.
3.1.1- MDA
MDA is a ketoaldehyde which is produced during the arachidonate metabolism as a
byproduct of peroxidation decomposition of lipids. The accumulation of MDA in an
injured tissue drives to a bond with some aminoacids (mainly with Lysine) altering
proteins and their biological functions. MDA could be found in many diseases such
as atherosclerosis or diabetes mellitus having a prediction function in the progression
of those diseases also including coronary artery disease or myocardium infarct.
In  atherosclerosis  MDA  interacts  with  the  protein  LDL  to  mediate  several
proinflammatory and proatherogenic processes that may generate foam cell leading to
coronary heart disease and strokes.
26
Figure 4: Molecular structure of MDA
Elevated concentrations of MDA adducts with Lysine have been found in samples of
women patients with preeclampsia, and also in plasma and breath in patients with
asthma.  Besides,  it  has  found  huge  levels  of  MDA in  diabetes  mellitus  patients
plasma  and  in  brains  of  people  who  suffer  from  Parkinson  disease.  Related
substances of MDA are the thiobarbituric acid-reactive substances which have been
determined in high levels in human plasma of people who have amyotrophic lateral
sclerosis or Alzheimer.
3.1.2- HNE
HNE  is  a  toxic  aldehyde  produced  by  a  free  radical  attack  on  omega-6-
polyunsaturated fatty  acids such as  arachidonic or  linoleic  acids.  HNE undergoes
many reaction with biomolecules and it is cytotoxic, mutagenic and genotoxic. It also
has several signal effects taking part in key processes such as inhibition of DNA
replication and protein synthesis, or inactivation of enzymes. 
Figure 5: Molecular structure of 4-HNE
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The usual concentration of HNE in human body is in the range from 0.1 to 3 µmol/L,
although in an oxidative stress situation its concentration raises hugely. HNE plays
the role of biomarker  in diseases  like Alzheimer  or  atherosclerosis,  together with
MDA. It is not an exclusive aging-disease biomarker but it is also present in other
illnesses such as mild cognitive impairment or rheumatologic diseases.
3.1.3- Isoprostanes
Isoprostanes are the result of a free radical reaction of peroxidation of arachidonic
acid.  F2-Isoprostanes  are  the most  studieds  due to  their  stability  in  human body.
These molecules haves renal and pulmonary vasoconstrictor function and they are
very useful as oxidative stress biomarkers in several health conditions. One of the
most remarkable case where isoprostanes are good biomarkers is in rhabdomyolysis,
a disease where myoglobin is released to plasma and then it can derive into a kidney
vasoconstriction.
Figure 6: Molecular structure of 8-iso-PGF2α 
Isoprostanes are easily found in almost every biological tissue or body fluids and they
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are able to be determined with different instrumental equipments from MS techniques
to immunoassays. The average concentration of each F2-Isoprostane in plasma are
less than 10 ng/L and it is known that they work as biomarkers in diseases like cystic
fibrosis,  asthma, acute chest  syndrome of sickle cell  disease or acute and chronic
alcoholic liver disease.
3.1.4- Glutathione
Glutathione and its  derivate  disulfide  glutathione concentration  are  determined  in
blood analysis  because  it  reflects  the whole body status  of  these molecules.  This
determination is usually done by MS-based techniques but it could be also analyzed
with other analytical techniques such as spectrophotometric and fluorometric assays.
In  contrast  with  the  other  mentioned  oxidative  stress  markers,  glutathione  levels
decrease when this stress happens, for example in aging. The decrease in glutathione
concentration  is  also  related  with  the  pathogenesis  of  several  diseases  such  as
rheumatoid arthritis,  amyotrophic lateral  sclerosis,  alcoholic liver  disease,  cataract
genesis,  respiratory  distress  syndrome  or  cardiovascular  disease  among  others.
Furthermore,  high  glutathione  levels  are  related  with  a  long  life-span  in  some
mammals and also in the elder population.
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Figure 7: Molecular structure of glutathione and its derivatives
3.2- Cancer
Nowadays,  several  ways  exist  to  do  a  metabolomic  cancer  analysis  [15].  The
scientists are able to carry it out  in vivo and  in vitro using a wide range of sample
types from tissues to the above commented biological fluids. With the objective of
reduce the difficulty of the analysis, biological fluids are usually used for their less
complex matrice being urine and plasma the most used among them.
However, the interest of the direct metabolomic analysis of the malignant tissue is
growing. Although, the complex task being the tissue preparation still remains the
biggest problem. There could be many different interferences which might be caused
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by the atmospheric conditions and the contamination from near healthy tissues.
It  is  important  to  know  the  common  and  general  methodologies  used  in  the
metabolomic  experiments  or  analysis.  I  is  essential  to  maintain  a  constant
temperature  and  to  do  the  sample  extraction  taking  care  to  avoid  possible
interferences. For biological fluids, the standard sample volume is in a range of 0,1-
0,5 mL. 
Remarkable discoveries have been done in the tumor metabolome in the last years. It
is  known that  phospholipids levels (characterized by a raise in choline-containing
compounds) and glycolytic functions are bigger than in a healthy tissue. Glycolytic
functions  include  an  increment  into the consumption  of  glucose  carbons to  drive
synthetic  processes,  high  glutaminolytic  function,  and  overexpression  of  the
glycolytic isoenzyme, pyruvate kinase type M2-PK (probably a tumor biomarker).
However,  metabolome  among  different  cancer  types  varies  making  it  difficult  to
generalize findings across tumor groups. Furthermore, the characterization of a tumor
could  be  hindered  by  several  variations  such  as  sample-to-sample  variation  or
sensitivity in extraction-based MS methods.  Some investigations [16] have shown
that a malignant phenotype in breast cancer could be detected from normal tissue by
choline-containing compounds  determination  with  a  sensitivity  around 100 %.  In
addition, a 68 % of biopsies could have been prevented following the choline method.
Another well-known case is prostate cancer,  where the malignant  tissue shows to
have a reduced level of citrate and a raise of spermine. This case fits with the high
concentration  of  choline  substances  pattern;  moreover  it  has  been  detected  high
lactate and alanine levels (both are glycolytic products).
Despite  its  complexity,  the  knowledge  about  metabolomics  in  brain  cancers  is
extensive.  Depending  on  the  tissue  there  several  subtypes  where  meningiomas,
neuroblastomas,  and  glioblastomas  are  the  most  commons.  There  are  differences
between  these  subtypes,  mainly  in  concentrations  of  substances  such  as  alanine,
glutamate,  creatine,  phosphorylcholine,  and threonine.  Brain cancers  presents  also
huge concentrations of total-choline compounds which could be used as a biomarker,
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but other variation is noticed with the decrease of N-acetyl aspartate concentration.
Ovarian  cancer  is  one  of  the  diseases  that  is  going to  be  comment  later  deeply.
However, it is interesting to comment the results of a study [17] carried out with
NMR  spectroscopy  and  with  samples  from healthy  women,  women  with  benign
ovarian cysts and women with preoperative ovarian cancer. The results showed that
the profiling, both in serum and in plasma, was able to establish patterns that varied
between the three sample groups. The next step was to determine if there was an
evident  variation  between tissue  invasive  carcinomas  and  superficial  tumors.  The
results  dropped  that  at  least  51  metabolites  could  be  used  as  biomarkers  for  the
identification  of  such  an  invasive  malignant  tumor  from  a  borderline  tumor.
Furthermore, the differences noted in these metabolites have previously been linked
to prognosis in ovarian cancer and correspond to pathways responsible for regulation
of pyrimidine metabolism.
4- Ovarian cancer
In this work the metabolomics main facts and features and also the cases of some
specific  diseases  such  as  oxidative  stress  diseases  and  cancer  have  already  been
commented. But, one objective about this work is to deep in to one specific disease
which is ovarian cancer. Metabolomics bring the bright of hope to the health world
because they make the scientists and doctors be able to predict a disease before it is
too late or use as a tool to identify if a treatment has a good response in the organism,
so it can be very useful to save lives.
Ovarian cancer (OC) is one of the leading causes of death from gynecologic diseases
in the developed world. Around the 80 % of people who suffer the advanced form of
this disease has a rate of survival from 15 % to 45 %. However, in patients who suffer
this disease in his first stage exist a survival rate of a 90 %. This difference between
stages  mortality  has  motivated  researchers  to  find  new  ways  of  diagnostic  and
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screening in  order  to  identify  the  malignancy  earlier  to  save  lives.  Although OC
knowledge has been spread and increased, there is still not a screening method which
ease the survival [18]. Some of the proposed methods are tests such as serum cancer
antigen  125  (CA-125),  ultrasound  imaging,  or  combination  of  both  of  them.
Nowadays, the screening with CA-125 is widely available but it has a low sensitivity
and  a  low predictive  value.  The  ultrasound  imaging  is  not  so  specific  with  ana
specificity range between 70 and 80 %, and it is also an operator-dependent screening
so  it  has  some  issues.  Despite  a  combination  of  both  gives  the  best  results,  the
technique is still under the required specificity and sensitivity levels of an effective
screening technique.
Another  important  issue  is  the  selected  biological  matrix  for  the  metabolomic
analysis. Despite several matrices give good results there are still some problems to
solve. In the case of serum analysis, the metabolomic analysis of OC patients confirm
that is able to improve the knowledge of the OC metabolome by identifying some
new biomarkers with high accuracy.  For urine samples,  the metabolomic analysis
shows the ability to identify some biomarkers of OC and distinguish them from breast
cancer.  However,  with  urine analysis  by  its  own it  is  not  possible  to  distinguish
between OC and cervical cancer.
In  order  to  elucidate  the  analyzed  biomarkers  and  metabolites  found  in  OC
metabolome data libraries are used. Most popular databases are Human Metabolome
Database,  MassBank,  KEGG and  METLIN and,  in  addition,  they  are  all  free  in
Internet. The last step is to determine and quantify an specific biomarker depending
on the researched aspect of the malignancy. This step is the most challenging of all,
because  the  complexity  of  identify  every  metabolite  that  acts  as  biomarker  [19].
However, in the last years several advances have been developed to make easier this
key step.  Vermeersch et al. affirmed that ability of metabolomics to measure high-
throughput, system-wide phenotypes give it significant potential power in the field of
oncology  to  understand  cancer  metabolism  and  carcinogenesis  while  allowing
biomarker discovery-based analysis [20].
33
Several methodologies could be used for detect and quantify metabolic biomarkers. A
targeted NMR approach was carried out by  Garcia et al. to diagnose the levels of
metabolites in patients serum with early OC [21]. There were 120 subjects and 132
controls. The results showed that there was an excellent separation between samples
and controls. Moreover, a comparison with biomarkers of renal cell carcinoma was
made and showed that this methodology was very sensitive to OC.
Another  experiment  [22]  was  performed  using  UHPLC-QTOF-MS to  distinguish
between biological patterns of early OC, benign tumors (BOT) and uterine fibroid
(UT). With this methodology the scientists were able to discriminate OC from BOT
with an area under the curve (AUC) of 0.910 and OC from UF with an AUC of
0.942. In addition, the profiling of metabolites in stage I showed that this method is
able to distinguish from advanced stages of OC, being 53 metabolites which acted as
biomarkers.  The  more  significant  are  lysophosphatidylethanolamines  (LPEs)  and
lysophosphatidylcholines  (LPCs).  In  addition,  the  experiments  showed  that  other
metabolites have their concentration altered in early OC cases. Those biomarkers are
imidazol-5-pyruvate, N4-acetylcytidine, pseudouridine, succinic acid, (S)-reticuline,
N-acetylneuraminic  acid,  3-sialyl-N-acetyllactos-amine,  β-  nicotinamide
mononucleotide, and 3-sialyllactose.  Besides, these biomarkers were not only useful
to differentiate between early and advanced OC, but also with benign tumors and
other ovarian diseases.
Several  studies  of  the  OC  metabolomics  revealed  that  there  are  also  altered
metabolites which proceed from different biological processes. These metabolites are
mainly  related  with  key  biological  pathways  such  as  cellular  respiration  or
carbohydrate  metabolism,  fatty  acid  oxidation,  aminoacids  metabolism  and,
nucleotide-related processes.
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4.1- Cellular respiration metabolites
The  cellular  respiration  metabolites  are  the  single  molecules  that  outcome  from
glycolysis, the Krebs cycle and anaerobic respiration. For these pathways, there are
several  changes  in  metabolites  concentration.  For  example,  the  levels  of  lactate
(metabolite derived from anaerobic glycolysis) increase in malignant cyst fluid, but
seem to decrease in serum and urine.
Glucose  levels  undergoes  changes  too,  they  increase  in  serum while  decrease  in
urine.  However,  glucose  levels  do  not  change  in  malignant  cyst  fluid  and  in
malignant tissues neither.
For Krebs cycle (or TCA cycle) three metabolites seem to change their concentration
in  human  body.  Malate  and  fumarate  levels  usually  increase  in  almost  every
biological fluid. In the other hand succinate shows contradictory results because it
sometimes presents low levels and others an increasing is observed.
4.2- Fatty acid oxidation metabolites
Free  fatty  acids  and  the  metabolites  produced  from their  oxidation  present  huge
changes in their concentration levels.  Several studies have reported high levels in
fatty acid oxidation metabolites, which are carnitine, acetylcarnitine, butyrylcarnitine,
propionylcarnitine and other carnitine derivated metabolites.
In general, the group of cholines usually increase their concentrations in patients with
early  and advanced OC.  Furthermore,  this  choline  levels  are  bigger  in  early  OC
patients than in the advanced disease.
Other molecules such as ceramides, gangliosides and lysophosphatidic acid (LPA)
were reported to be in high levels in serum, urine and ascitic fluid for  early and
advanced OC patients. Increased levels of long chain fatty acids and their esters have
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been noticed in malignant  tissues and serum. The more remarkable  are palmitate,
myristate and oleate.
To finish,  Buas et al. [23] used lipidomics profiling and identified 17 metabolites
including glycerolipids and glycerophospholipids that were decreased in OC cases.
4.3- Aminoacids metabolites
Amnoacids  and  aminoacids  metabolism  metabolites  present  changes  in  their
concentrations,  but  not  every metabolite  presents a continuous variation.  Some of
these molecules are alanine and valine where some studies reported oscillation in
their levels for OC patients.
Levels of aminoacids which are donors of nitrogen usually increase in serum, urine
and metastatic tissue of people who have OC.
Zhou et al. [24] found increased levels of cysteine, glycine, and threonine using MS
platforms.
Altered levels of metabolites and aminoacids involved in L-tryptophan metabolism
was shown in OC with decreased plasma and serum levels  of  tryptophan and its
metabolites 3-indolepropionic acid and 5-hydroxyindoleacetaldehyde as  Hilvo et al.
[25] reported. It was also found that in L-tryptophan degradations 3-indolelactic acid
levels  increased  in  urine  and  kynurenine  levels  increased  in  serum,  plasma  and
malignant tissue.
Several metabolites with origin in phenylalanine catabolism present altered levels for
OC early and advanced patients.  Phenylpyruvate, phenyllactate,  and phenylacetate
are the mentioned metabolites.  Phenylalanine levels in serum decrease because of
their  enhanced  catabolism,  but  hippuric  acid,  a  by-product  of  phenylalanine
production, decrease its levels in urine.
The L-histidine, another aminoacid, appear to low its concentration in urine, serum
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and  plasma  for  early  OC  patients.  Furthermore,  the  product  of  L-histidine
metabolism, imidazol-5-yl-pyruvate, seems to be at higher levels in OC patients. This
fact probably means that enhanced metabolism of this aminoacid occurs.
Finally,  Fong  et  al.  [26] confirmed  that  some  brain  aminoacids  such  as  N-
acetylaspartate  (NAA)  and  its  derivative  N-acetylaspartatyl-glutatmate  (NAAG)
appear in higher conditions than standard levels for metastatic OC patients.
4.4- Nucleotide metabolites
The most of registered metabolomic patterns related with nucleotides and nucleotides
metabolites are about regulation of purine and pyrimidine metabolism.  Chen et al.
[27] reported that pseudouridine was commonly found to be elevated in urine and
serum, while hypoxanthine was found elevated in serum, malignant cyst fluid and
malignant  tissue.  Elevated  levels  of  1-methyladenosine,  3-methyluridine,  N4-
acetylcytidine and urate-3-ribonucleoside in urine were also reported.
4.5- Other metabolites
In this section the more remarkable and abundant metabolites which are not related
with an specific pathway are going to be commented.
First, several studies such as the carried out by Hilvo et al. [25] confirmed that ketone
levels in serum usually increase in patients with OC. For example, 3-hydroxybutyrate
levels  seems  to  increase  in  high  quantities  specially  for  metastatic  patients.
Acetoacetate, acetone, 3,4- dihydroxybutyric and 2,4-dihydroxybutyric acid are other
ketone bodies  that  show an increase on their  levels  and concentrations in  human
serum  for  people  suffering  from  OC.  In  addition,  other  species  such  as  2-
hydroxybutyric  acid,  and  α,  δ  and  γ-tocopherol  have  an  elevation  in  their
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concentration too.
Other  studies  have  found  altered  histamine  metabolites  in  early  OC  patients.
Furthermore,  Zhou  et  al.  [24]  demonstrated  that  a  significant  fraction  from  the
metabolites found in serum of OC cases have their origin in histamine pathway.
4.6- Discussion
Main metabolites  that  act  as  biomarkers  in key biological  processes have already
been commented.  However,  in  this  section  this  topic  is  going to  be  discussed  in
detail.
The  OC  cases  present  some  altered  metabolites  for  the  cellular  respiration  in
glycolysis, the Krebs cycle and anaerobic respiration and that reflects an alteration in
energy  obtaining.  The  alteration  in  energy  metabolism  was  discovered almost  a
century ago and received the name of Warburg effect in honor of his finder. This
phenomenon was demonstrated  with several  metabolomics  analysis,  confirming it
with  increased  levels  of  glucose  6-phosphate  and  glucose  1-phosphate  in  cancer
tissue.  The Warburg effect  is  known to enhance  the production of  lactate  and to
reduce the pH of the cancer environment, causing impairs DNA repair mechanisms.
However, in reviewed studies there is a lack in the consistence of lactate increasing
and it is remarkable the increase of Krebs cycle intermediates (aerobic respiration)
despite  of  Warburg  effect.  This  phenomenon  could  be  explained  by  anaplerosis
process.  As  commented  by  DeBerardinis  et  al.  [28]  this  mechanism  refers  to
replenishment  of  intermediates  through  the  generation  of  α-  ketoglutarate  from
glutamate following its conversion from glutamine, generating macromolecules that
are essential for cellular proliferation.
Moreover, the substrates of two enzymes which take part in Krebs cycle (succinate
dehydrogenase and fumarate hydratase) are identified as onco-metabolites  and the
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inhibition of these enzymes leads to an increase of succinate and fumarate levels. The
raise of these two metabolites has been clearly related with patients who suffer from
early OC. These alterations of Krebs cycle intermediates and their enzymes suggest a
big demand of energy, and that is a known feature about a malignant tissue which is
growing.
Lipids metabolism is another key biological process that presents altered metabolites
for  OC  patients.  The  main  reason  to  relate  ovarian  malignancy  with  the  altered
oxidation of lipids is that the adipocytes act as a reservoir of energy for proliferant
cancer cells. This fact was supported when beta oxidation of fatty acids appeared to
be altered in several malignant tissues such as prostate and kidney [29]. Moreover,
Derdak et al. [30] confirmed that increased fatty acid oxidation is associated with an
over-expression of uncoupling proteins that can promote chemoresistance in cancer
cells  through  mitochondrial  “uncoupling,”  helping  cancer  cells  to  survive.  This
oxidation is manifested as an elevated concentration of carnitine proteins in serum,
plasma and malignant tissue from OC cases.
The enhanced oxidation of lipids involves also an altered function of acetyl-CoA.
This molecule usually enters in Krebs cycle, however due to the altered turnover of
this  process,  metabolites  leads  to  deplete  oxaloacetate  levels  in  the  liver.  This
phenomenon drives in turn to an hindrance for acetyl-CoA to enter in Krebs cycle so
the molecule is converted into ketone bodies which could be good biomarkers for
early OC.
The enhanced fatty acid oxidation leads to altered metabolism of sphingolipid and
glycerolipid as well as to altered levels of long chain fatty acids. Several studies [23]
have confirmed by lipidomics profiling in OC samples that there is a decrease in at
least  17  metabolites  which  are  mainly  glycerolipids  and  glycerophospholipids.
Furthermore, elevated levels of lysophosphatidylcholine (LPC) and  lysophosphatidic
acid (LPA) were previously reported as possible biomarkers for early and advanced
OC. In order to distinguish early OC from metastatic OC some studies carried out by
Ke  et  al.  [22] in  2015  revealed  that  there  is  a  difference  in  LPCs  and  LPEs
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(lysophosphatidylethanolamines) levels depending on how advanced is the disease. In
early OC disease levels of LPCs and LPEs seem to be altered and they are higher
than in metastatic  OC showing a potential biomarker to distinguish between both
health status and to know more about the progression of the disease.
The experiments of Coussens and Werb [31] confirmed that sphingolipids and fatty
acids have cellular signal transduction activity that contributes to genetic instability
and cancer initiation.
Amino acid metabolism is another key biological pathway that is commonly altered
in cancer cells. For example, the high cell cycle turnover cause an increased uptake of
glutamine in cancer cells. Glutamine is a key aminoacid because it plays a role as the
amino  group  donor  for  many  biosynthetic  pathways.  Not  only  glutamine  but
glutamate  show altered  levels  in  metabolic  profiling  studies  of  serum,  cyst  fluid,
urine and tumor  tissue.  Other  aminoacids  such as  alanine,  glycine,  threonine and
cysteine show elevated concentrations in patients with OC. These aminoacids have a
huge biological relevance because of their function in protein biosynthesis so their
altered levels indicate the rapid cell cycling and high turnover of cancer metabolism.
The  degradation  of  L-tryptophan  in  OC  patients  is  one  of  the  immune  resistant
mechanism that OC disease has. Platten et al. [32] said that the enhanced degradation
of tryptophan leads to T cell  anergy and apoptosis via the GCN2 pathway, while
increased levels of the tryptophan breakdown product kynurenine suppresses T cell
differentiation.  This  process  has  been  studied  largely  during  the  years  and  it  is
confirmed by metabolomics studies (Ke et al. [22]) with decreased plasma levels of
L-tryptophan  and  its  metabolites  (5-hydroxyindoleacetaldehyde  and  3-
Indolepropionic acid). Furthermore, principal metabolites coming from phenylalanine
metabolism (phenylpyruvate and phenylacetate) seem to have elevated concentrations
in the serum and malignant tissue of  early OC while the levels of phenylalanine
appear to decrease  in serum (enhanced catabolism of phenylalanine). Additionally,
benzoate  degradation  is  known to  be  a  part  of  phenylalanine  pathway,  which  is
associated with altered hippurate levels [22]. Decrease of hippurate levels in serum is
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a common phenomenon in OC patients. Despite of the several OC-related findings in
phenylanine pathway, there is still not clear the role in OC of this molecule and their
metabolites. 
Another  substance,  the  L-histidine  show  decreased  levels  in  serum and  urine  in
profiling studies carried out by Ke et al. [22] and Zhang et al. [33]. Further, in these
studies  elevated  levels  of  midazol-5-yl-pyruvate,  a  L-histidine  degradation
metabolite, which is probably caused by an enhanced metabolism of this aminoacid.
In addition, the enzyme histidine decarboxylase converts histidine to histamine. Over
the  past  decade,  considerable  data  suggest  an  important  function  of  histamine  in
malignant cell proliferation [34]. Histamine works as a receptor-dependent growth
factor  in  malignant  tissues  for  OC  and  also  in  breast  cancer  and  in  malignant
melanoma.
Based on the nucleotide-related metabolites, it is a fact that nucleotide metabolism is
enhanced in OC disease. The tumor growth is dependent from the synthesis of  new
purine and pyrimidine  nucleotides.  However,  there  is  still  not  enough knowledge
about nucleotide pathways in OC pathogenesis.
To finish, another altered metabolite in OC disease is the tocopherol. The isoforms α,
β,  δ,  and  γ  of  tocopherol  are  known to  have  antioxidant  activity  and  possess  a
protective effect against many cancers [35]. Fong et al. [26] found increased levels of
α ,δ and γ tocopherol in metastatic OC but he did not find altered concentrations of
any tocopherol in early OC. This difference could be explained by the fact that this
metabolic alteration develops during the metastatic stage.
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5- Conclusion
In this work, the most important aspects of metabolomics have been discussed, from
the most general ones to end up focusing on clinical metabolomics. Aspects such as
the two types of metabolomic approaches with their advantages and disadvantages
have been reviewed.  The metabolomic  workflow usually followed in this  kind of
studies has also been reviewed and the main analytical instruments used have been
slightly  commented.  The  main  biological  matrices  that  could  be  found  in  these
analyses  have  also  been  treated.  Afterwards,  the  current  applications  have  been
discussed along with a small perspective of how metabolomics could be useful for the
medical  world  in  the  future.  Finally,  we have  focused  mainly  on two groups  of
diseases, those caused by oxidative stress and cancers.In the last group of diseases we
have gone even deeper since ovarian cancer was the target of the experimental work
that could not be carried out due to the state of alarm declared in March. 
It  is  important  to  add  that  our  original  work  was  mainly  oriented  towards  the
metabolomic approach of fingerprinting, as almost all references reviewed on OC are
focused on profiling specific  metabolites  from presumable  altered pathways..  The
aim was to perform an external validation of a predictive model of optimal surgery in
ovarian cancer. The aim was to perform an untargeted metabolomic analysis in order
to optimize certain prognostic factors to predict the response to treatment. It was also
intended to help improve and personalize treatments as well as to be able to relate the
levels of certain metabolites as markers of recurrence when monitoring a patient after
or during the treatment.
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